Please ensure Javascript is enabled for purposes of website accessibility

European Medicines Agency Offers Free Advice for Drugmakers Working on Coronavirus Treatments

By Mark Prvulovic - Mar 16, 2020 at 4:33PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The EU's medical regulator is looking to help, and to gain insight about where its resources can best be deployed.

As the COVID-19 pandemic in Europe continues to escalate, top healthcare organizations across the continent are doing everything in their power to assist companies in developing a treatment. The European Medicines Agency (EMA), the EU's medical regulator, announced Friday that it would offer free scientific advice and assistance to drugmakers that are working on COVID-19 vaccines or treatments.

It was a significant announcement considering that the EMA typically charges from around $48,000 to $97,000 for scientific advice. The agency provided a dedicated email address for inquiries and urged biotech companies to reach out should they need assistance.

Two scientists having a discussion while looking at a computer screen.

Image source: Getty Images.

"In a first round of discussions, EMA can provide preliminary informal comments and feedback on development. This will then allow the agency to identify products which are mature enough to benefit from fast-track scientific advice, to guarantee best use of this too," said the agency.

Further details

There are around 179,000 confirmed COVID-19 cases across the world at the moment, and the death toll has topped 7,000. Although the number of new infections in China seems to have peaked and declined to below 100 a day, Europe has seen an explosion in cases. Italy has around 28,000 confirmed COVID-19 patients, with more than 3,000 diagnosed Monday, and the country's healthcare system is struggling to cope.

While there are a number of companies developing treatments for the novel coronavirus, most aren't going to be available for a while, even if they prove effective. Gilead (GILD 0.26%) has an antiviral drug called remdesivir currently undergoing phase 3 trials as a COVID-19 treatment in China. Moderna (MRNA 7.95%) is also attempting to develop a SARS-CoV-2 vaccine -- its phase 1 clinical trial began Monday.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Gilead Sciences, Inc. Stock Quote
Gilead Sciences, Inc.
GILD
$62.89 (0.26%) $0.16
Moderna, Inc. Stock Quote
Moderna, Inc.
MRNA
$172.24 (7.95%) $12.68

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
322%
 
S&P 500 Returns
113%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/07/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.